Literature DB >> 26524744

Dosing Strategies of Bone-Targeting Agents.

Brian Hutton1, Sasha Mazzarello2, Mark Clemons2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26524744     DOI： 10.1001/jamainternmed.2015.4789

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  3 in total

1.  Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.

Authors:  Mashari Alzahrani; Carol Stober; Michelle Liu; Arif Awan; Terry L Ng; Gregory Pond; Bader Alshamsan; Lisa Vandermeer; Mark Clemons
Journal:  Support Care Cancer       Date:  2022-01-21       Impact factor: 3.603

2.  Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.

Authors:  Mark Clemons; Michelle Liu; Carol Stober; Gregory Pond; Mashari Jemaan Alzahrani; Michael Ong; Scott Ernst; Christopher Booth; Mihaela Mates; Anil Abraham Joy; Olexiy Aseyev; Phillip Blanchette; Lisa Vandermeer; Megan Tu; Kednapa Thavorn; Dean Fergusson
Journal:  J Bone Oncol       Date:  2021-09-02       Impact factor: 4.072

3.  A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.

Authors:  Mark Clemons; Michael Ong; Carol Stober; Scott Ernst; Christopher Booth; Christina Canil; Mihaela Mates; Andrew Robinson; Phillip Blanchette; Anil Abraham Joy; John Hilton; Olexiy Aseyev; Gregory Pond; Ahwon Jeong; Brian Hutton; Sasha Mazzarello; Lisa Vandermeer; Igal Kushnir; Dean Fergusson
Journal:  Eur J Cancer       Date:  2020-10-03       Impact factor: 9.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.